Epoch and Specialty Labs to develop assays:
This article was originally published in Clinica
Genomic and molecular diagnostics company Epoch Biosciences and Specialty laboratories, a specialised medical testing service, are to jointly develop highly sensitive assays to determine whether abnormal cells remain in the bloodstream following treatment to eradicate leukaemia. Redmond, Washington-based Epoch will develop probes for the assays, while Specialty, of Santa Monica, California, will develop and clinically evaluate the assays. It will also offer them commercially under a licence granted by Epoch.